EBOVAC 2: Evaluation of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults and Children

Ebola vaccine

Janssen Vaccines & Prevention B.V.



The purpose of EBOVAC 2 study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo. The study includes healthy adults and elderly participants, HIV infected participants and healthy children in 2 age strata.   EBOVAC2 has been awarded a "Star of Europe" Special Prize by the French Ministry of Research in 2021. This trophy aims at rewarding and valorizing the European commitment of the research teams which have distinguished themselves by the success of their projects.  

Role of EUCLID

  • Methodology
  • Statistical aspects
  • Data management
  • Global coordination of the trial


Similar projects